• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Aging . Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults

tetano

Editor, Senior Moderator
Nat Aging


. 2022 Oct;2(10):896-905.
doi: 10.1038/s43587-022-00292-y. Epub 2022 Oct 14. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults

Miguel Ángel Palacios-Pedrero[SUP] #[/SUP][SUP] 1 [/SUP], Janina M Jansen[SUP] #[/SUP][SUP] 1 [/SUP], Cornelia Blume[SUP] 2 [/SUP], Nils Stanislawski[SUP] 3 [/SUP], Rebecca Jonczyk[SUP] 2 [/SUP], Antonia Molle[SUP] 1 [/SUP], Mariana Gonzalez Hernandez[SUP] 1 [/SUP], Franziska K Kaiser[SUP] 1 [/SUP], Klaus Jung[SUP] 4 [/SUP], Albert D M E Osterhaus[SUP] 1 5 [/SUP], Guus F Rimmelzwaan[SUP] 6 [/SUP], Giulietta Saletti[SUP] 7 [/SUP]



Affiliations
Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is effective in preventing COVID-19 hospitalization and fatal outcome. However, several studies indicated that there is reduced vaccine effectiveness among older individuals, which is correlated with their general health status[SUP]1,2[/SUP]. How and to what extent age-related immunological defects are responsible for the suboptimal vaccine responses observed in older individuals receiving SARS-CoV-2 messenger RNA vaccine, is unclear and not fully investigated[SUP]1,3-5[/SUP]. In this observational study, we investigated adaptive immune responses in adults of various ages (22-99 years old) receiving 2 doses of the BNT162b2 mRNA vaccine. Vaccine-induced Spike-specific antibody, and T and memory B cell responses decreased with increasing age. These responses positively correlated with the percentages of peripheral naïve CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells and negatively with CD8[SUP]+[/SUP] T cells expressing signs of immunosenescence. Older adults displayed a preferred T cell response to the S2 region of the Spike protein, which is relatively conserved and a target for cross-reactive T cells induced by human 'common cold' coronaviruses. Memory T cell responses to influenza virus were not affected by age-related changes, nor the SARS-CoV-2-specific response induced by infection. Collectively, we identified signs of immunosenescence correlating with the outcome of vaccination against a new viral antigen to which older adults are immunologically naïve. This knowledge is important for the management of COVID-19 infections in older adults.


 
Back
Top Bottom